References

The Parkinson's-Reversing Breakthrough

Diets for Parkinson Disease

Get Instant Access

1. Birkmayer W, Hornykiewicz O. Der 1-3,4 Dioxyphenylalanin (=DOPA)- Effekt bei der Parkinson-Akinese. Wien J Klin Wochenschr 1961; 73:787-788.

2. Barbeau A, Sourkes TL, Murphy CF. Les catecholamines dans la maladie de Parkinson. In: de Ajuriaguerra J, ed. Monoamines et Systeme Nerveaux Central. Geneva: Gerog, 1962:247-262.

3. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276:374-379.

4. Carlsson A, Lindquist M, Magnusson T. 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180:200.

5. Bertler A, Rosengren E. Occurrence and distribution of catecholamines in brain. Acta Physiol Scand 1959; 47:350-361.

6. Ehringer H, Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems . Wien Klin Wochenschr 1960; 38:1236-1239.

7. Anden NE, Carlsson A, Dahlstrom A, et al. Demonstration and mapping of nigroneos-triatal dopamine neurons. Life Sci 1964; 3:523-530.

8. Poirier LJ, Sourkes TL. Influence of the substantia nigra on the catecholamine content of the striatum. Brain 1965; 88:181-192.

9. Axelrod J. Catecholamine neurotransmitters, psychoactive drugs, and biological clocks. The 1981 Harvey Cushing oration. J Neurosurg 1981; 55(5):669-677.

10. Axelrod J. The O-methylation of epinephrine and other catechols in vitro and in vivo. Science 1957; 126:1657-1660.

11. Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27(2):135-206.

12. Shaw KNF, McMillan A, Armstrong MD. The metabolism of 3,4-dihydroxyphenylalanine. J Biol Chem 1957; 226(1):255-266.

13. Carlsson A. Functional significance of drug-induced changes in brain monoamine levels. In: Himwich HE, Himwich WA, eds. Biogenic Amines (Progress in Brain Research. Vol. 8). Amsterdam: Elsevier, 1964:9-27.

14. Nissinen E, Tuominen R, Perhoniemi V, et al. Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci 1988; 42(25):2609-2614.

15. Schultz E, Nissinen E. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem Pharmacol 1989; 38(22):3953-3956.

16. Mannisto PT, Ulmanen I, Lundstrom K, et al. Characteristics of catechol-O-methyl transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992; 39:291-350.

17. Ding YS, Gatley SJ, Fowler JS, et al. Mapping catechol-O-methyltransferase in vivo: initial studies with [18F] Ro41-0960. Life Sci 1996; 58(3):195-208.

18. Teravainen H, Rinne U, Gordin A. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Adv Neurol 2001; 86:311-325.

19. Tai CH, Wu RM. Catechol-O-methyltransferase and Parkinson's disease. Acta Med Okayama 2002; 56:1-6.

20. Huotari M, Gogos JA, Karayiorgou M, et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 2002; 15(2):246-256.

21. Grossman MH, Emanuel BS, Budarf ML. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics 1992; 12(4):822-825.

22. Lee MS, Kim HS, Cho EK, et al. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 2002; 58(4):564-567.

23. Olanow CW, Schapira AHV, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000; 23(suppl):S117-S126.

24. Rinne UK, Sonninen V, Siirtola T. Treatment of parkinsonian patients with levodopa and extracerebral decarboxylase inhibitor, Ro 4-4602. In: Calne D, ed. Progress in the Treatment of Parkinsonism (Advances in Neurology. Vol. 3). New York: Raven Press, 1973:59-71.

Porter CC. Inhibitors of aromatic amino acid decarboxylase - their biochemistry. In: Yahr MD, ed. Treatment of Parkinsonism - The Role of Dopa Decarboxylase Inhibitors (Advances in Neurology. Vol. 2). New York: Raven Press, 1973:37-58. Bacq ZM, Gosselin L, Dresse A, et al. Inhibition of O-methyltransferase by catechol and sensitization to epinephrine. Science 1959; 130(3373):453-454.

Axelrod J, LaRoche MJ. Inhibitor of O-methylation of epinephrine and norepinephrine in vitro and in vivo. Science 1959; 130:800.

Ericsson AD. Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J Neurol Sci 1971; 14(2):193-197.

Reches A, Fahn S. Catechol-O-methyltransferase and Parkinson's disease. Adv Neurol 1984; 40:171-179.

Linden IB, Nissinen E, Etemadzadeh E, et al. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J Pharmacol Exp Ther 1988; 247(1):289-293.

Tornwall M, Mannisto PT. Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission. Pharmacol Toxicol 1991; 69(1):64-70.

Cedarbaum JM, Leger G, Reches A, et al. Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys. Clin Neuropharmacol 1990; 13(6):544-552.

Marcocci L, Maguire JJ, Packer L. Nitecapone: a nitric oxide radical scavenger. Biochem Mol Biol Int 1994; 34(3):531-541.

Nissinen E, Linden IB, Schultz E, et al. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur J Pharmacol 1988; 153(2-3):263-269. Schultz E, Tarpila S, Backstrom AC, et al. Inhibition of human erythrocyte and gastro-duodenal catechol-O-methyltransferase activity by nitecapone. Eur J Clin Pharmacol 1991; 40(6):577-580.

Kaakkola S, Gordin A, Jarvinen M, et al. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-Dopa in healthy volunteers. Clin Neu-ropharmacol 1990; 13(5):436-447.

Najib J. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther 2001; 23(6):802-832.

Heikkinen H, Nutt JG, LeWitt PA, et al. The effects of different repeated doses of enta-capone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. Clin Neuropharmacol 2001; 24(3):150-157.

Keranen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of enta-capone. Eur J Clin Pharmacol 1994; 46:151-157.

Keranen T, Gordin A, Harjola V-P, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993; 16(2):145-156.

Nissinen E, Linden I-B, Schultz E, et al. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 1992; 346(3):262-266.

Brannan T, Prikhojan A, Yahr MD. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism. J Neural Transm 1997; 104(1):77-87.

Keranen T, Gordin A, Karlsson M, et al. Effect of the novel catechol-O-methyltransferase inhibitor OR-611 in healthy volunteers. Neurology 1991; 41(suppl):213. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996; 19(4):283-296.

Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995; 18(1):46-57. Rouru J, Gordin A, Huupponen R, et al. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. Eur J Clin Pharmacol 1999; 55(6):461-467.

47. Heikkinen H, Saraheimo M, Antila S, et al. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique. Eur J Clin Pharmacol 2001; 56(11):821-826.

48. Kaakkola S, Teravainen H, Ahtila S, et al. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994; 44(1):77-80.

49. Schapira AHV, Obeso JA, Olanow CW. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology 2000; 55(suppl 4):S65-S68.

50. Nutt JG. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 2000; 55(suppl 4):S33-S37.

51. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997; 42(5):747-755.

52. Kieburtz K, Hubble J. Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials. Neurology 2000; 55(suppl 4):S42-S45.

53. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease. Vol. 2. New York: McMillan, 1987:153-163.

54. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998; 51(5):1309-1314.

55. Larsen JP, Worm-Petersen J, Siden A, et al. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 2003; 10(2):137-146.

56. Durif F, Devaux I, Pere JJ, et al. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 2001; 45(2):111-118.

57. Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen Study). Acta Neurol Scand 2002; 105(4):245-255.

58. Fenelon G, Gimenez-Roldan S, Montastruc JL, et al. Efficacy and tolerability of enta-capone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicenter study. J Neural Transm 2003; 110(3):239-251.

59. Piccini P, Brooks DJ, Korpela K, et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 68(5):589-594.

60. Stocchi F, Barbato L, Nordera G, et al. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. J Neural Transm 2004; 111(2):173-180.

61. Brusa L, Pierantozzi M, Bassi A, et al. Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome. Neurol Sci 2004; 25(2):53-56.

62. Paija O, Laine K, Kultalahti E-R, et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharma-col 2005; 28(3):115-119.

63. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365(9463):947-954.

64. Kupsch A, Trottenberg T, Bremen D. Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study. Curr Med Res Opin 2004; 20(1): 115-120.

65. Gershanik O, Emre M, Bernhard G, et al. Efficacy and safety of levodopa with enta-capone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicenter, open-label study. Prog Neuropsy-chopharmacol Biol Psychiatry 2003; 27(6):963-971.

66. Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's disease

(PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicenter open-label study. J Neural Transm 2004; 111(8):1053-1063.

67. Parashos SA, Wielinski CL, Kern JA. Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease. Clin Neuropharmacol 2004; 27(3):119-123.

68. Fisher A, Croft-Baker J, Davis M, et al. Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord 2002; 17(6):1362-1365.

69. Bares M, Kanovsky P, Rektor I. Excessive daytime sleepiness and "sleep attacks" induced by entacapone. Fundam Clin Pharmacol 2003; 17(1):113-116.

70. Orama M, Tilus P, Taskinen J, et al. Iron (III)-chelating properties of the novel catechol-O-methyltransferase inhibitor entacapone in aqueous solution. J Pharm Sci 1997; 86(7): 827-831.

71. Coudore F, Durif F, Duroux E, et al. Effect of tolcapone on plasma and striatal apomor-phine disposition in rats. Neuroreport 1997; 8(4):877-880.

72. Zijlmans JCM, Debilly B, Rascol O, et al. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Mov Disord 2004; 19(9):1006-1011.

73. O'Suilleabhain PE, Bottiglieri T, Dewey RB Jr, et al. Modest increase in plasma homocys-teine follows levodopa initiation in Parkinson's disease. Mov Disord 2004; 19(12): 1403-1408.

74. Miller JW, Selhub J, Nadeau MR, et al. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003; 60(7):1125-1129.

75. Muller T, Werne B, Fowler B, et al. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 1999; 354(9173):126-127.

76. Rogers JD, Sanchez-Saffon A, Frol AB, et al. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003; 60(1):59-64.

77. Yasui K, Nakaso K, Kowa H, et al. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003; 108(1):66-67.

78. Bots ML, Launer LJ, Lindemans J, et al. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J Intern Med 1997; 242(4):339-347.

79. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999; 131(5):352-355.

80. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346(7):476-483.

81. Tiemeier H, van Tuijl HR, Hofman A, et al. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002; 159(12):2099-2101.

82. Valkovic P, Benetin J, Blazicek P, et al. Reduced plasma homocysteine levels in lev-odopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005; 11(4): 253-256.

83. Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005; 20(1):69-72.

84. Brooks DJ, Agid Y, Eggert K, et al. Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo® (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess®/Comtan® (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 2005; 53(4):197-202.

85. Koller W, Guarnieri M, Hubble J, et al. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 2005; 112(2):221-230.

86. Silver DE. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo®). Expert Rev Neurotherapeutics 2004; 4(4):589-599.

87. Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology 2004; 62(1 suppl 1):S64-S71.

88. Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/ entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Curr Med Res Opin 2005; 21(7):1005-1014.

89. Jorga KM. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology 1998; 50(suppl 5):S31-S38.

90. Dingemanse J, Jorga K, Zurcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995; 40(3):253-262.

91. Jorga KM, Fotteler B, Heizmann P, et al. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Clin Pharmacol 1998; 54(5):443-447.

92. Dingemanse J. Issues important for rational COMT inhibition. Neurology 2000; 55(suppl 4):S24-S27.

93. Jorga K, Fotteler B, Heizmann P, et al. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br J Clin Pharmacol 1999; 48(4):513-520.

94. Da Prada M, Borgulya J, Napolitano A, et al. Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect. Clin Neuropharmacol 1994; 17(suppl 3):S26-S37.

95. Dingemanse J. Catechol-O-methyltransferase inhibitors: clinical potential in the treatment of Parkinson's disease. Drug Dev Res 1997; 42:1-25.

96. Zurcher G, Dingemanse J, Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv Neurol 1993; 60:641-647.

97. Thiffault C, Langston JW, Di Monte DA. Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. Exp Neurol 2003; 183(1):173-179.

98. Ceravolo R, Piccini P, Bailey DL, et al. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002; 43(3):201-207.

99. Russ H, Muller T, Woitalla D, et al. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol 1999; 360(6):719-720.

100. Sedek G, Jorga K, Schmitt M, et al. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol 1997; 20(6):531-541.

101. Kurth MC, Adler CH. COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology 1998; 50(suppl 5):S3-S14.

102. Kurth MC, Adler CH St, Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tol-capone Fluctuator Study Group I. Neurology 1997; 48(1):81-87.

103. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa. Tol-capone Fluctuator Study Group III. Arch Neurol 1998; 55(8):1089-1095.

104. Rajput AH, Martin W, Saint-Hilaire M-H, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49(4):1066-1071.

105. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing-off " phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63(4):421-428.

106. Koller W, Lees A, Doder M, et al. Randomized trial of tolcapone versus pergolide as addon to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001; 16(5):858-866.

107. Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov Disord 1999; 14(1):38-44.

108. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004; 4:CD004553.

109. Larsen KR, Dajani EZ, Dajani NE, et al. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs. Dig Dis Sci 1998; 43(8):1806-1813.

110. Watkins P. COMT inhibitors and liver toxicity. Neurology 2000; 55(suppl 4):S51-S52.

111. Benabou R, Waters C. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease. Expert Opin Drug Saf 2003; 2(3):263-267.

112. Borges N. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf 2005; 4(1):69-73.

113. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66(7):983-995.

114. Nissinen E, Kaheinen P, Penttila KE, et al. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur J Pharmacol 1997; 340(2-3):287-294.

115. Korlipara LVP, Cooper JM, Schapira AHV. Differences in toxicity of the catechol-O-methyl transferase inhibitor, tolcapone and entacapone to cultured human neurob-lastoma cells. Neuropharmacology 2004; 46(4):562-569.

116. Smith KS, Smith PL, Heady TN, et al. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chen Res Toxicol 2003; 16(2):123-128.

117. Keating GM, Lyseng-Williamson KA. Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs 2005; 19(2):165-184.

118. Nuijten MJ, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health 2001; 4:316-328.

119. Hudry J, Rinne JO, Keranen T, et al. Cost utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. Ann Pharmacother 2006; 40(4):651-657.

120. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 1997; 49(3):665-671.

121. Dupont E, Burgunder J-M, Findley LJ, et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo- controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II). Mov Disord 1997; 12(6):928-934.

122. Hauser RA, Molho E, Shale H, et al. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Mov Disord 1998; 13(4):643-647.

123. Brooks DJ, Sagar H, the UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo-controlled, double blind, six-month study. J Neurol Neurosurg Psychiatry 2003; 74(8):1071-1079.

124. Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of enta-capone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004; 61(10):1563-1568.

125. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998; 50(suppl 5):S17-S25.

126. Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000; 23(suppl):S86-S91.

127. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease. Implications for the early use of COMT inhibitors. Neurology 2000; 55(suppl 4):S72-S77.

128. Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004; 62(1 suppl 1):S72-S81.

129. Smith LA, Jackson MJ, Al-Barghouthy G, et al. Multiple small doses of levodopa plus enta-capone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005; 20(3):306-314.

Was this article helpful?

0 0
Unraveling Alzheimers Disease

Unraveling Alzheimers Disease

I leave absolutely nothing out! Everything that I learned about Alzheimer’s I share with you. This is the most comprehensive report on Alzheimer’s you will ever read. No stone is left unturned in this comprehensive report.

Get My Free Ebook


Post a comment